Orpheon Finance Press Releases

• Published on June 24, 2024 - 15:03 GMT

  SYNERGIA MEDICAL NOMINEE FOR PRESTIGIOUS 2024 INTERNATIONAL PRIX GALIEN FOR ITS OPTOELECTRONIC NEUROSTIMULATOR

  BRUSSELS, BELGIUM, June 24, 2024 /⁨EINPresswire.com⁩/ -- Synergia Medical, a preclinical medical device company that has developed NAO.VNS, the first optoelectronic neurostimulator for the treatment of drug-resistant epilepsy through Vagus Nerve …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on April 29, 2024 - 17:45 GMT

  SYNERGIA MEDICAL OBTAINS BELGIUM HEALTH AUTHORITY APPROVAL TO START FIRST IN HUMAN CLINICAL STUDY

  Synergia Medical to start NAO.VNS FIH study, the first quartz optoelectronic neurostimulator for the treatment of drug-resistant epilepsy. BRUSSELS, BELGIUM, April 29, 2024 /⁨EINPresswire.com⁩/ -- Synergia Medical, a clinical medical device company that …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on March 17, 2023 - 09:18 GMT

  

  SYNERGIA MEDICAL WINS PRESTIGIOUS PRIX GALIEN IN BELGIUM FOR ITS OPTOELECTRONIC NEUROSTIMULATOR

  Synergia Medical is pleased to announce that they have been awarded the Prix Galien 2023 in Belgium for promising medical devices. BELGIUM, March 17, 2023 /⁨EINPresswire.com⁩/ -- Synergia Medical, a preclinical medical device company that has developed …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on February 24, 2023 - 08:41 GMT

  ReST Therapeutics receives endorsement from the EMA to enter clinical phase & request First in Human trials for FENM®

  ReST Therapeutics is developing breakthrough therapies to treat Alzheimer Disease (AD) and PTSD with its flagship product FENM®. MONTPELLIER, FRANCE, February 24, 2023 /⁨EINPresswire.com⁩/ -- ReST Therapeutics, clinical-stage biotech company developing …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on January 18, 2023 - 08:35 GMT

  SYNERGIA MEDICAL INCREASES SERIES B FUNDING TO €12.8 MILLION WITH AN ADDITIONAL €3.8 MILLION

  Synergia Medical announced the completion of an additional €3.8 million of Series B funding, allowing the preparation for FIH clinical trials planned for 2024 BELGIUM, January 18, 2023 /⁨EINPresswire.com⁩/ -- Synergia Medical, a preclinical medical device …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on November 28, 2022 - 14:49 GMT

  

  SYNERGIA MEDICAL STRENGTHENS ITS MANAGEMENT TEAM WITH THE APPOINTMENT OF DAN SCHERRER AS COO

  Synergia Medical announced today the appointment of Dan Scherrer as Chief Operating Officer who brings over 20 years of experience in the medical device field. BELGIUM, November 28, 2022 /⁨EINPresswire.com⁩/ -- Drug Resistant Epilepsy Treatment Belgium …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on October 20, 2022 - 09:04 GMT

  SYNERGIA MEDICAL RECOGNISED BY EIC ACCELERATOR FOR THE EXCELLENT POTENTIAL OF ITS EPILEPSY TREATMENT SOLUTION

  Synergia Medical announced a €2.5 million grant from the EIC program with a potential equity investment in the future Series C fund raising of €7.5 million. BRUXELLES, BELGIUM, October 20, 2022 /⁨EINPresswire.com⁩/ -- Drug Resistant Epilepsy Treatment …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on September 12, 2022 - 11:36 GMT

  

  SYNERGIA MEDICAL SUCCESSFULLY RAISES SERIES B FUNDING OF €9 MILLION

  Synergia Medical, a preclinical medical device company, today announced the successful completion of a €9 million Series B funding round. BRUSSELS, BELGIUM, September 12, 2022 /⁨EINPresswire.com⁩/ -- Drug Resistant Epilepsy Treatment SYNERGIA MEDICAL …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...